Publications

Hassoun-Kheir N. et al, (2022), Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health.

Gardiner E. et al, (2022), Journal of mental health (Abingdon, England), 31, 524 - 533

Serological Evidence of Human Infection With Avian Influenza A(H7N9) Virus: A Systematic Review and Meta-analysis.

Wang W. et al, (2022), The Journal of infectious diseases, 226, 70 - 82

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

Abbas A. et al, (2022), Scientific Data, 9

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Abani O. et al, (2022), The Lancet, 400, 359 - 368

Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.

Peto L. et al, (2022), Advances in biological regulation

Whole-genome sequencing reveals host factors underlying critical COVID-19.

Kousathanas A. et al, (2022), Nature, 607, 97 - 103

Ebola virus disease in pregnancy: a systematic review and meta-analysis

Kayem ND. et al, (2022), Transactions of The Royal Society of Tropical Medicine and Hygiene, 116, 509 - 522

Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

Knight SR. et al, (2022), Thorax, 77, 606 - 615

Why preprints are good for patients

Horby P., (2022), Nature Medicine, 28, 1109 - 1109

Allocated but not treated: the silent 16%

Horby P. et al, (2022), LANCET, 399, 1776 - 1776

Allocated but not treated: the silent 16% – Authors' reply

Horby P. et al, (2022), The Lancet, 399, 1775 - 1776

Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years.

van Beek J. et al, (2022), Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 27

COVID-19 can be called a treatable disease only after we have antivirals.

Zhang X. et al, (2022), Science bulletin, 67, 999 - 1002

The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations.

Goossens H. et al, (2022), The Lancet. Infectious diseases, 22, e153 - e158

Innovations in public health surveillance: updates from a forum convened by the WHO Hub for Pandemic and Epidemic Intelligence, 2 and 3 February 2022.

Technical contributors to the Pandemic and Epidemic Intelligence Innovation Forum February meeting and report None., (2022), Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 27

Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing

Salam AP. et al, (2022), PLOS Neglected Tropical Diseases, 16, e0010289 - e0010289

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Horby PW. et al, (2022)

The effect of hand hygiene frequency on reducing acute respiratory infections in the community: a meta-analysis.

Mo Y. et al, (2022), Epidemiology and infection, 150

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Abani O. et al, (2022), The Lancet, 399, 665 - 676

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Cookies on this website

Publications